Physician profile
Mazen Khalil
NPI 1659323608
$17,801.38
in general payments reported to CMS, 2019-2025
77 companies · $2,928 in 2025
The $2,928 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $3,346 · 2020: $1,372 · 2021: $1,830 · 2022: $2,258 · 2023: $2,942 · 2024: $3,126 · 2025: $2,928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,919 · Education: $77.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,918.51 |
| Education | $77.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,375.85 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $1,232.21 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $1,141.78 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,101.29 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $860.32 | 2019-2025 | Opdualag, Opdivo |
| Amgen INC. | $827.27 | 2019-2023 | Kyprolis, Lumakras, Nplate |
| Janssen Biotech, INC. | $766.61 | 2019-2025 | Erleada, Balversa, Akeega |
| Daiichi Sankyo INC. | $713.28 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Abbvie INC. | $585.98 | 2019-2025 | |
| Genzyme Corporation | $567.62 | 2019-2025 | |
| Eisai INC. | $533.10 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $506.81 | 2019-2025 | Ninlaro, Iclusig, Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $395.25 | 2021-2025 | Libtayo |
| Glaxosmithkline, LLC. | $360.17 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Celgene Corporation | $313.08 | 2019-2025 | Pomalyst, Opdualag, Reblozyl |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $306.37 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Bayer Healthcare Pharmaceuticals INC. | $296.09 | 2019-2025 | |
| Incyte Corporation | $293.46 | 2019-2025 | Monjuvi, Jakafi |
| Seagen INC. | $281.31 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Emd Serono, INC. | $275.67 | 2021-2025 | Bavencio |
| Exelixis INC. | $269.62 | 2019-2025 | Cabometyx |
| Karyopharm Therapeutics INC. | $246.61 | 2020-2022 | |
| Puma Biotechnology, INC. | $233.06 | 2019-2025 | |
| Genentech USA, INC. | $223.51 | 2019-2025 | Tecentriq, Phesgo, Polivy |
| G1 Therapeutics, INC. | $217.38 | 2022-2023 | Cosela |
| Sumitomo Pharma America, INC. | $212.65 | 2023-2025 | Orgovyx |
| Lilly USA, LLC | $212.05 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Gilead Sciences, INC. | $192.56 | 2021-2025 | Trodelvy |
| Kyowa Kirin, INC. | $191.96 | 2019-2025 | Poteligeo |
| Ipsen Biopharmaceuticals, INC | $188.08 | 2021-2025 | Onivyde, Tazverik |
| Pharmacyclics LLC, An Abbvie Company | $183.97 | 2019-2023 | Epkinly, Imbruvica |
| Beigene USA, INC. | $182.67 | 2020-2025 | Brukinsa |
| Pharmaessentia USA Corporation | $149.89 | 2023 | Besremi |
| Astellas Pharma US INC | $145.46 | 2019-2025 | Xospata, Xtandi, Vyloy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.07 | 2020-2025 | Gilotrif |
| Foundation Medicine, INC. | $135.83 | 2019-2020 | |
| Deciphera Pharmaceuticals INC. | $131.40 | 2021-2025 | Qinlock, Romvimza |
| Acrotech Biopharma INC. | $123.37 | 2024-2025 | Beleodaq |
| Myovant Sciences INC. | $119.59 | 2021-2022 | |
| Adc Therapeutics America, INC. | $115.89 | 2022-2024 | |
| Intera Oncology, INC | $107.69 | 2024 | Intera |
| Alexion Pharmaceuticals, INC. | $107.22 | 2019-2022 | |
| Sobi, INC | $105.99 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $89.50 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $80.51 | 2019-2024 | Rezlidhia, Tavalisse |
| Beone Medicines USA, INC. | $80.37 | 2025 | Brukinsa |
| Global Blood Therapeutics, INC. | $72.88 | 2021-2022 | |
| Tersera Therapeutics LLC | $70.22 | 2021-2025 | Zoladex |
| Dova Pharmaceuticals | $66.31 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $59.99 | 2019 | |
| Amag Pharmaceuticals, INC. | $57.32 | 2019-2021 | |
| Clovis Oncology, INC. | $54.85 | 2019 | |
| Aveo Pharmaceuticals, INC. | $47.91 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $45.66 | 2023 | Empaveli |
| Iovance Biotherapeutics, INC. | $44.82 | 2025 | Amtagvi |
| Alnylam Pharmaceuticals INC. | $42.95 | 2020-2025 | Amvuttra |
| Mirati Therapeutics, INC. | $32.43 | 2023 | Krazati |
| Servier Pharmaceuticals LLC | $31.75 | 2021-2022 | |
| Abiomed | $27.80 | 2025 | |
| Cti Biopharma Corp. | $26.28 | 2022-2023 | Vonjo |
| Tempus Ai, INC | $20.12 | 2024 | |
| Novocure INC. | $17.72 | 2023 | Optune |
| Kite Pharma, INC. | $17.37 | 2024 | Yescarta |
| Portola Pharmaceuticals, LLC | $17.36 | 2019 | |
| Ethicon US, LLC | $16.67 | 2025 | Echelon Flex |
| Geron Corporation | $15.04 | 2025 | Rytelo |
| Caris Mpi, INC. | $14.86 | 2025 | Mi Cancer Seek |
| Morphosys, US INC. | $13.98 | 2023 | Monjuvi |
| Agios Pharmaceuticals, INC. | $13.26 | 2019 | |
| Dendreon Pharmaceuticals LLC | $12.47 | 2022 | |
| Epizyme, INC. | $11.60 | 2021 | |
| Acceleron Pharma, INC. | $11.19 | 2021 | |
| Taiho Oncology, INC. | $11.05 | 2021 | |
| Secura Bio, INC. | $9.10 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$10,541.08 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazen Khalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.